Chidamide-BEAC plus autologous stem cell transplantation in high-risk non-Hodgkin lymphoma:a phase II clinical trial  

作　　者：Yi Xia Li Wang Kaiyang Ding Jiazhu Wu Hua Yin Maogui Hu Haorui Shen Jinhua Liang Ruize Chen Yue Li Huayuan Zhu Jianyong Li Wei Xu 

机构地区：[1]Department of Hematology,The First Affiliated Hospital of Nanjing Medical University,Jiangsu Province Hospital,Nanjing,Jiangsu 210029,China [2]Key Laboratory of Hematology of Nanjing Medical University,Nanjing,Jiangsu 210029,China [3]Collaborative Innovation Center for Cancer Personalized Medicine,Nanjing,Jiangsu 210029,China [4]Department of Hematology,The First Affiliated Hospital of USTC Anhui Provincial Hospital,Hefei,Anhui 230001,China [5]National Clinical Research Center for Hematologic Diseases,The First Affiliated Hospital of Soochow University,Suzhou,Jiangsu 215000,China

出　　处：《Chinese Medical Journal》2023年第12期1491-1493,共3页中华医学杂志（英文版）

基　　金：National Natural Science Foundation of China(Nos.81770166,81700193,82170186 and 81720108002);Jiangsu Province’s Medical Elite Programme(No.ZDRCA2016022);Project of National Key Clinical Specialty,Jiangsu Provincial Special Program of Medical Science(No.BE2017751);National Science and Technology Major Project(No.2018 ZX09734007);China Postdoctoral Science Foundation(No.2021M691336);Jiangsu Postdoctoral Science Foundation(No.2021K083A);Translational Research Grant of NCRCH(No.2020ZKZB01)

摘　　要：To the Editor:Non-Hodgkin lymphoma(NHL)is a common type of hematological malignancy.Although the development of targeted therapies has improved the survival of patients with aggressive NHL,autologous hematopoietic stem cell transplantation(HSCT)remains indispensable.There is no standard conditioning regimen for autologous stem cell transplantation(ASCT).

关 键 词：AUTOLOGOUS LYMPHOMA NHL 

分 类 号：R457.7[医药卫生—治疗学] R733.1[医药卫生—临床医学]